Article
A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
Methods (San Diego, Calif.) - 15 Jun 2015
Gauthier Marie-Soleil, Pérusse Joëlle R, Awan Zuhier, Bouchard Annie, Tessier Sylvain, Champagne Josée, Krastins Bryan, Byram Gregory, Chabot Katherine, Garneau Pierre, Rabasa-Lhoret Rémi, Faubert Denis, Lopez Mary F, Seidah Nabil G, Coulombe Benoit
Abstract excerpt
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating low density lipoprotein cholesterol (LDL-C) levels. Besides its full-length mature form, multiple variants of PCSK9 have been reported such as forms that are truncated, mutated and/or with posttranslational modifications (PTMs). Previous studies have demonstrated that most of these variants affect PCSK9's function and thereby...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.